SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-029097
Filing Date
2024-02-29
Accepted
2024-02-29 08:12:43
Documents
16
Period of Report
2024-02-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm247462d1_8k.htm   iXBRL 8-K 27403
2 EXHIBIT 99.1 tm247462d1_ex99-1.htm EX-99.1 180432
6 GRAPHIC tm247462d1_ex99-1img001.jpg GRAPHIC 23097
  Complete submission text file 0001104659-24-029097.txt   430966

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vyne-20240229.xsd EX-101.SCH 3042
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vyne-20240229_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vyne-20240229_pre.xml EX-101.PRE 22377
17 EXTRACTED XBRL INSTANCE DOCUMENT tm247462d1_8k_htm.xml XML 3614
Mailing Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 24699005
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)